Amphastar P

Yahoo Finance • 2 days ago

Align Technology, Envista, Centene, Amphastar Pharmaceuticals, and Oscar Health Shares Plummet, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. The president's tone and the suggestion of canceling... Full story

Yahoo Finance • last month

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Presents a Compelling Value Investment Case

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH [https://www.chartmill.com/stock/quote/AMPH/profile]) has been identified as a potential candidate for value investors through a screening process that emphasizes strong fundamental valuation whil... Full story

Yahoo Finance • 2 months ago

Bullish Two Hundred Day Moving Average Cross - AMPH

In trading on Friday, shares of Amphastar Pharmaceuticals Inc (Symbol: AMPH) crossed above their 200 day moving average of $47.00, changing hands as high as $48.04 per share. Amphastar Pharmaceuticals Inc shares are currently trading up a... Full story

Yahoo Finance • 2 months ago

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vi... Full story

Yahoo Finance • 2 months ago

Amphastar boosts pipeline with exclusive licensing deal from Nanjing Anji

Amphastar Pharmaceuticals (NASDAQ:AMPH [https://seekingalpha.com/symbol/AMPH]) has entered [https://seekingalpha.com/pr/20197044-amphastar-pharmaceuticals-bolsters-proprietary-pipeline-through-exclusive-licensing-agreement] into an exclusi... Full story

Yahoo Finance • 2 months ago

Amphastar stock rises after FDA approves generic iron sucrose injection

Investing.com -- Amphastar Pharmaceuticals (NASDAQ:AMPH) stock gained 4% after the company announced FDA approval for its generic version of iron sucrose injection, a treatment for iron deficiency anemia in patients with chronic kidney dis... Full story

Yahoo Finance • 2 months ago

Piper Sandler lowers Amphastar Pharmaceuticals stock price target on competitive headwinds

Investing.com - Piper Sandler lowered its price target on Amphastar Pharmaceuticals (NASDAQ:AMPH) to $25.00 from $30.00 on Friday, while maintaining a Neutral rating on the stock. The stock, currently trading at $21.62, is near its 52-week... Full story

Yahoo Finance • 2 months ago

Amphastar advances U.S. manufacturing expansion and signals flat 2025 revenue outlook amid competitive pressures

Earnings Call Insights: Amphastar Pharmaceuticals (AMPH) Q2 2025 MANAGEMENT VIEW * Dan Dischner, Senior Vice President of Corporate Communications, highlighted that Amphastar delivered a solid performance in Q2 2025, underpinned by "th... Full story

Yahoo Finance • 3 months ago

Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White... Full story

Yahoo Finance • 3 months ago

JPMorgan Downgrades Amphastar Pharmaceuticals (AMPH) to Neutral from Overweight, Brings PT Down to $30

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On May 12, JPMorgan downgraded Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to Neutral from Overweight, while also reducing... Full story

Yahoo Finance • 3 months ago

Amphastar Pharmaceuticals stock hits 52-week low at 22.6 USD

Amphastar Pharmaceuticals (NASDAQ:AMPH) stock reached a 52-week low, trading at 22.6 USD. According to InvestingPro analysis, the company appears undervalued despite maintaining strong fundamentals with a P/E ratio of 7.88 and healthy liqu... Full story

Yahoo Finance • 7 months ago

On Nasdaq, I Prefer the Less-Famous Stocks

March 17, 2025 (Maple Hill Syndicate) - The Nasdaq Stock Market led the way up in the great rally of the past two years. Now it's leading the way down. Nasdaq is home to most big technology stocks and many small stocks. The Nasdaq Composi... Full story

Yahoo Finance • last year

Amphastar Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Amphastar Pharmaceuticals (NASDAQ:AMPH) Second Quarter 2024 Results Key Financial Results Revenue: US$182.4m (up 25% from 2Q 2023). Net income: US$37.9m (up 45% from 2Q 2023). Profit margin: 21% (up from 18% in 2Q 2023). The increase in... Full story

Yahoo Finance • 2 years ago

Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / January 2, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Dr. Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 42nd Annual J.P. Morgan Healthcare C... Full story

Yahoo Finance • 2 years ago

Insider Sell Alert: Director Richard Prins Sells 4,000 Shares of Amphastar Pharmaceuticals Inc ...

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has recently witnessed an insider sell that has caught the attention of investors and market analysts. On November 17, 2023, Director Richard Prins sold 4,000 shares of the company, a transaction... Full story

Yahoo Finance • 2 years ago

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023

Reports Net Revenues of $180.6 Million for the Three Months Ended September 30, 2023 RANCHO CUCAMONGA, CA / ACCESSWIRE / November 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported result... Full story

Yahoo Finance • 2 years ago

Is Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Latest Stock Performance A Reflection Of Its Financial Health?

Amphastar Pharmaceuticals' (NASDAQ:AMPH) stock is up by a considerable 52% over the past three months. Given the company's impressive performance, we decided to study its financial indicators more closely as a company's financial health ov... Full story

Yahoo Finance • 2 years ago

Elon Musk Plans Next Starship Launch Within Two Months, NBCUniversal CEO Resigns Amid 'Inappropriate Relationship, Micron Tech Caught Between US-China Tensions: Today's Top Stories

Benzinga Elon Musk Plans Next Starship Launch Within Just 2 Months After Failed Debut SpaceX CEO Elon Musk on Saturday said that Starship could be ready to launch again in 1 to 2 months. Starship can be ready to launch again in 1 to 2 mo... Full story

Yahoo Finance • 3 years ago

Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5

The top five biotech stocks today have several commonalities: strong ratings, promising charts and membership on the IBD Tech Leaders list.... Full story

Yahoo Finance • 3 years ago

Value Hedge Funds are Winning in 2022 Thanks to These 15 Stocks

In this article, we discuss the value hedge funds winning in 2022 and the 15 stocks that helped them do it. If you want to read about some more value stocks, go directly to Value Hedge Funds are Winning in 2022 Thanks to These 5 Stocks. E... Full story